Who would have thought that cow's milk could help your brain? ReGen Therapeutics did. Its main product is Colostrinin, a polypeptide nutraceutical derived from ovine and bovine colostrums (the first milk produced after the birth of an offspring) that has been shown to have neurological benefits for sufferers of ailments such as Alzheimer's disease and multiple sclerosis. The supplement is marketed as CogniSure by licensee
Track this company’s financial condition.
View Company Report
Request Your Free Trial
| Income Statement | 2012 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
| Revenue | $-0.3149835 | $0.0891856 | $0.1331516 | $0.1277632 | $0.793071 |
| Gross Profit | $-0.3149835 | $0.07166700000000001 | $0.10420560000000001 | $0.07985199999999999 | $0.38380719999999996 |
| Operating Income | $-1.0547909 | $-1.2008204 | $-2.1955541 | $-5.2642431 | $-4.5469404 |
| Net Income | $-1.0547909 | $-1.162598 | $-2.1173999 | $-4.7611755 | $-4.2610432 |
| Diluted EPS | $0.0 | $-0.04 | $-0.18 | $-0.51 | $-0.78 |
| Cash Flow (mil) | 2012 | 2009 | 2008 |
|---|---|---|---|
| Cash at the beginning of the year | $ | $0.0361825 | $1.1738244 |
| Net Operating Cash | $-0.3731343 | $-0.8791152 | $-1.3329633 |
| Net Investing Cash | $0.2180655 | $-0.0684818 | $-0.1461773 |
| Net Financing Cash | $0.1082251 | $0.9603378 | $0.6643107 |
| Net Change in Cash | $-0.0468437 | $0.0127408 | $-0.8148299 |
| Cash at end of the year | $0.0064612 | $0.047778 | $0.0361825 |
| Capital Expenditure | $ | $-0.0684818 | $-0.1606503 |
| Assets (mil) | 2012 | 2009 | 2008 |
|---|---|---|---|
| Current Assets | |||
| Cash | $0.0064612 | $0.047778 | $0.0361825 |
| Net Receivables | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Income Assets | $0.0371519 | $0.2165936 | $0.2836708 |
| Asset Summary | |||
| Total Current Assets | $0.0436131 | $0.2643716 | $0.3198533 |
| Net Fixed Assets | $ | $ | $0.0014473 |
| Other Noncurrent Assets | $0.1114557 | $2.4908264 | $2.5458007 |
| Total Assets | $0.1550688 | $2.755198 | $2.8671012 |
| Liabilities (mil) | 2012 | 2009 | 2008 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $0.2002972 | $0.493706 | $0.6064187 |
| Short Term Debt | $ | $ | $ |
| Other Current Liabilities | $0.0193836 | $0.1704082 | $0.1765706 |
| Liability Summary | |||
| Total Current Liabilities | $0.2196808 | $0.6641142 | $0.7829893 |
| Long Term Debt | $ | $ | $ |
| Other Noncurrent Liabilities | $0.0 | $0.15926 | $0.14473 |
| Total Liabilities | $0.2196808 | $0.8233742 | $0.9277193 |
| Stakeholder's Equity (mil) | 2012 | 2009 | 2008 |
|---|---|---|---|
| Equity | |||
| Preferred Stock Equity | $ | $ | $ |
| Common Stock Equity | $-0.064612 | $1.9318238 | $1.939382 |
| Equity Summary | |||
| Total Equity | $-0.064612 | $1.9318238 | $1.939382 |
| Shares Outstanding | 443.14 | 36.73 | 15.11 |